Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study

PD-1 rechallenge strategies showed measurable antitumor activity and manageable safety profile in a subset of previously immunotherapy-treated advanced NSCLC. Limitations existed in this study and the findings were descriptive and hypothesis-generating and should be interpreted cautiously because treatment selection was non-random and important confounders might be incompletely captured.